Cover Image

Integrating proteomics into precision oncology

DNA sequencing and RNA sequencing are increasingly applied in precision oncology, where molecular tumor boards evaluate the actionability of genetic events in individual tumors to guide targeted treatment. To work toward an additional level of patient characterization, we assessed the abundance and...

Full description

Saved in:
Bibliographic Details
Main Authors: Wahjudi, Leonie (Author) , Bernhardt, Stephan (Author) , Abnaof, Khalid (Author) , Horak, Peter (Author) , Kreutzfeldt, Simon (Author) , Heining, Christoph (Author) , Borgoni, Simone (Author) , Becki, Corinna (Author) , Berg, Daniela (Author) , Richter, Daniela (Author) , Hutter, Barbara (Author) , Uhrig, Sebastian (Author) , Pfütze, Katrin (Author) , Leichsenring, Jonas (Author) , Glimm, Hanno (Author) , Brors, Benedikt (Author) , Kalle, Christof von (Author) , Stenzinger, Albrecht (Author) , Korf, Ulrike (Author) , Fröhling, Stefan (Author) , Wiemann, Stefan (Author)
Format: Article (Journal)
Language:English
Published: 15 March 2021
In: International journal of cancer
Year: 2021, Volume: 148, Issue: 6, Pages: 1438-1451
ISSN:1097-0215
DOI:10.1002/ijc.33301
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1002/ijc.33301
Verlag, lizenzpflichtig, Volltext: https://www.onlinelibrary.wiley.com/doi/abs/10.1002/ijc.33301
Get full text
Author Notes:Leonie W. Wahjudi, Stephan Bernhardt, Khalid Abnaof, Peter Horak, Simon Kreutzfeldt, Christoph Heining, Simone Borgoni, Corinna Becki, Daniela Berg, Daniela Richter, Barbara Hutter, Sebastian Uhrig, Katrin Pfütze, Jonas Leichsenring, Hanno Glimm, Benedikt Brors, Christof von Kalle, Albrecht Stenzinger, Ulrike Korf, Stefan Fröhling, Stefan Wiemann
Description
Summary:DNA sequencing and RNA sequencing are increasingly applied in precision oncology, where molecular tumor boards evaluate the actionability of genetic events in individual tumors to guide targeted treatment. To work toward an additional level of patient characterization, we assessed the abundance and activity of 27 proteins in 134 patients whose tumors had previously undergone whole-exome and RNA sequencing within the Molecularly Aided Stratification for Tumor Eradication Research (MASTER) program of National Center for Tumor Diseases, Heidelberg. Proteomic and phosphoproteomic targets were selected to reflect the most relevant therapeutic baskets in MASTER. Among six different therapeutic baskets, the proteomic data supported treatment recommendations that were based on DNA and RNA analyses in 10% to 57% and frequently suggested alternative treatment options. In several cases, protein activities explained the patients' clinical course and provided potential explanations for treatment failure. Our study indicates that the integrative analysis of DNA, RNA and protein data may refine therapeutic stratification of individual patients and, thus, holds potential to increase the success rate of precision cancer therapy. Prospective validation studies are needed to advance the integration of proteomic analysis into precision oncology.
Item Description:First published: 19 September 2020
Gesehen am 02.10.2020
Physical Description:Online Resource
ISSN:1097-0215
DOI:10.1002/ijc.33301

Similar Items